ClinicalTrials.gg
CompletedNCT02287233Updated Aug 29, 2022Results posted

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

A Phase 1/2 interventional study of Venetoclax and Cytarabine in Acute Myelogenous Leukemia and AML, sponsored by AbbVie. Completed at 9 sites in 4 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2022-08-29.

Sponsored by AbbVie · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
94
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Enrollment
78th of 202
94 · median 57
Started
2014
with 3 others
Phase 1/2
28 of 202
12 open now
Registered
6th of 202
by date
Lead sponsor
15 of 202
AbbVie

Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 78th largest by enrollment, is one of 4 that started in 2014, is one of 28 in phase 1/2, and was the 6th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This study consists of two parts: A Phase 1 dose-escalation part that will evaluate the safety and pharmacokinetic profile of venetoclax in combination with low-dose cytarabine (LDAC), define the maximum tolerated dose (MTD), and generate data to support a recommended Phase 2 dose (RPTD) in treatment-naïve participants with acute myelogenous leukemia (AML); and a Phase 2 part that will evaluate if the RPTD has sufficient efficacy and acceptable toxicity to warrant further development of the combination therapy.

03

Conditions studied

  • Acute Myelogenous Leukemia
  • AML

Keywords

  • Myelogenous Leukemia
  • Treatment Naive AML
  • Untreated AML
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be greater than or equal to 65 years of age in Phase 1 and 2. Participants enrolled in Cohort C must be either:

    • greater than or equal to 75 years of age; OR
    • greater than or equal to 60 to 74 years will be eligible if the participants has at least one of the following co-morbidities, which make the participant unfit for intensive chemotherapy:

      • (ECOG) Performance Status of 2 - 3;
      • Cardiac history of congestive heart failure (CHF) requiring treatment or less than or equal to 50% or chronic stable angina;
      • Diffusion capacity of carbon monoxide (DLCO) less than or equal to 65% or (FEV1) less than or equal to 65%;
      • greater than or equal to 30 mL/min to less than 45 ml/min (calculated by Cockcroft-Gault formula)
      • Moderate hepatic impairment with total greater than 1.5 to less than or equal to 3.0 × (ULN)
      • Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the study medical monitor before study enrollment
  • Participant must have a projected of at least 12 weeks.
  • Participant must have histological confirmation of AML and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidity or other factors.
  • Participant must have received no prior treatment for AML with the exception of hydroxyurea, allowed through the first cycle of study treatment. Note: Participant may have been treated for prior Myelodysplastic Syndrome.
  • Participant must have an ECOG performance status:

    • of 0 to 2 for participants greater than equal to 75 years of age
    • of 0 to 3 for participants greater than equal to 60 to 74 years of age, if 0 - 1 another co-morbidity is required to make participant eligible.
  • Participant must have adequate renal function as demonstrated by a creatinine clearance greater than or equal to 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula.
  • Participant must have adequate liver function as demonstrated by:

    • (AST) less than or equal to 2.5 × ULN
    • alanine aminotransferase (ALT) less than or equal to 2.5 × ULN
    • bilirubin less than or equal to 1.5 × ULN for all participants age 75 and older

      • Participants who are less than 75 years of age must have a bilirubin of less than 3.0 × ULN.

Note: Participants with Gilbert's Syndrome may have a bilirubin greater than 1.5 × ULN per discussion between the investigator and AbbVie medical monitor.

  • Male participants must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 180 days after the last dose of study drug.
  • Participant must voluntarily sign and date an , approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.
  • If female, participant must be either:

    • defined as no menses for 12 or more months without an alternative medical cause OR
    • Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)

Exclusion criteria

Exclusion Criteria:

  • Participant has received treatment with cytarabine for a pre-existing myeloid disorder.
  • Participant has acute promyelocytic leukemia (French-American-British Class M3 AML).
  • Participant has known active central nervous system (CNS) involvement with AML.
  • Participant has tested positive for (HIV).
  • Participant has received the following within 7 days prior to the initiation of study treatment:

    • Strong and moderate inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort.
  • Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of study treatment.
  • Participant has a cardiovascular disability status of Class greater than 2.
  • Participant has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study.
  • Participant has chronic respiratory disease that requires continuous oxygen use.
  • Participant has a malabsorption syndrome or other condition that precludes enteral route of administration.
  • Participant exhibits evidence of other uncontrolled condition(s) including, but not limited to:

    • Uncontrolled systemic infection requiring intravenous (IV) therapy (viral, bacterial or fungal).
  • Participant has a history of other prior to study entry, with the exception of:

    • Adequately treated in situ carcinoma of the breast or cervix uteri;
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
  • Participant has a white blood cell count greater than 25 × 10\^9/L. Note: Hydroxyurea is permitted to meet this criterion.
  • Participant is a candidate for a bone marrow or stem cell transplant within 12 weeks after study enrollment.
  • Participant has a history of myeloproliferative neoplasm (MPN) including polycythemia vera, myelofibrosis, essential thrombocythemia, or chronic myelogenous leukemia.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Phase 1: 600 mg Venetoclax + LDAC

    Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg (Day 2) and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received low-dose cytarabine (LDAC; 20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle. Participants could continue receiving treatment until disease progression or until discontinuation criteria were met.

    Drug: Venetoclax · Drug: Cytarabine

  • Experimental
    Phase 1: 800 mg Venetoclax + LDAC

    Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 100 mg (Day 2) and increased up to 800 mg by Day 6. Beginning with Cycle 2, 800 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle. Participants could continue receiving treatment until disease progression or until discontinuation criteria were met.

    Drug: Venetoclax · Drug: Cytarabine

  • Experimental
    Phase 2: 600 mg Venetoclax + LDAC

    Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg, and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle. Participants could continue receiving treatment until disease progression or until discontinuation criteria were met.

    Drug: Venetoclax · Drug: Cytarabine

Interventions

  • Venetoclax will be taken orally once daily.

    Also known as: GDC-0199, ABT-199, VENCLEXTA®

  • Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Dose-limiting Toxicities

    Dose-limiting toxicities (DLTs) were determined during cycle 1 of the dose-escalation phase and defined as Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 grade 4 (life threatening requiring urgent intervention) or 5 (resulted in death) toxicity, excluding adverse events commonly caused by AML (eg, neutropenia, fever). Hematologic DLT was defined as failure of platelet recovery to 25 × 10\^9/L or greater and absolute neutrophil count (ANC) to 0.5 × 10\^9/L or greater within 14 days of the last dose of venetoclax in the absence of residual AML.

    Time frame: Up to 28 days (Cycle 1)

  2. Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax

    The highest concentration that a drug achieves in the blood after administration in a dosing interval.

    Time frame: Cycle 1, Day 10 at predose and 2, 4, 6, 8, and 24 hours postdose (venetoclax with LDAC); Cycle 1, Day 18 at predose, 2, 4, 6, 8, and 24 hours postdose (venetoclax alone)

  3. Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax

    The time at which the maximum plasma concentration (Cmax) is observed.

    Time frame: Cycle 1, Day 10 at predose and 2, 4, 6, 8, and 24 hours postdose (venetoclax with LDAC); Cycle 1, Day 18 at predose, 2, 4, 6, 8, and 24 hours postdose (venetoclax alone)

  4. Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax

    Time frame: Cycle 1, Day 10 at predose and 2, 4, 6, 8, and 24 hours postdose (venetoclax with LDAC); Cycle 1, Day 18 at predose, 2, 4, 6, 8, and 24 hours postdose (venetoclax alone)

  5. Phase 1: Maximum Observed Plasma Concentration (Cmax) of Cytarabine

    The highest concentration that a drug achieves in the blood after administration in a dosing interval.

    Time frame: Cycle 1, Day 1 and Day 10 at pre-dose and at 15 and 30 minutes and 1, 3, 6 hours post-dose.

  6. Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Cytarabine

    The time at which the maximum plasma concentration (Cmax) is observed.

    Time frame: Cycle 1, Day 1 and Day 10 at pre-dose and at 15 and 30 minutes and 1, 3, 6 hours post-dose.

  7. Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to Last Measurable Concentration (AUCt) of Cytarabine

    Time frame: Cycle 1, Day 1 and Day 10 at pre-dose and at 15 and 30 minutes and 1, 3, 6 hours post-dose.

  8. Overall Response Rate

    Overall response rate (ORR) is defined as the percentage of participants who achieved a complete remission (CR), complete remission with incomplete marrow recovery (CRi), or partial remission (PR) per the International Working Group (IWG) for AML response criteria, per investigator assessment. CR: absolute neutrophil count (ANC) ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, red blood cell (RBC) transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRi: lack of morphologic evidence of leukemia (blasts \< 5%), and platelet counts \< 10\^5 /µL or ANC \< 10\^3 /µL. PR: all of the hematologic values for a CR but with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate.

    Time frame: Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.

  9. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator rated the severity of each AE according to the CTCAE Version 4.0 and the following: Grade 1: The AE is transient and easily tolerated (mild). Grade 2: The AE causes discomfort and interrupts usual activities (moderate). Grade 3: The AE causes considerable interference with usual activities and may be incapacitating (moderate to severe). Grade 4: The AE is life threatening requiring urgent intervention. Grade 5: The AE resulted in death. The investigator assessed each event as either having a reasonable possibility or no reasonable possibility of being related to the use of study drug. Treatment-emergent events are defined as events that began or worsened in severity after the first dose of study drug.

    Time frame: From first dose of study drug until 30 days after last dose of study drug; median (minimum, maximum) duration of treatment was 4.1 (0.2, 62.8) months overall.

Secondary outcomes

  1. Complete Remission Rate

    Complete remission (CR) rate is defined as the percentage of participants who achieved a complete remission at any time point during the study per the modified IWG criteria for AML and investigator assessment. CR: absolute neutrophil count (ANC) ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, red blood cell (RBC) transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. Participants who never achieved CR or had no IWG disease assessment were considered to be non-responders in the calculation of CR rate.

    Time frame: Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.

  2. Complete Remission Plus CR With Incomplete Blood Count Recovery (CRi) Rate

    The percentage of participants who achieved a CR or CRi at any time point during the study per the modified IWG criteria for AML and investigator assessment. CR: absolute neutrophil count (ANC) ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, red blood cell (RBC) transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRi: lack of morphologic evidence of leukemia (blasts \< 5%), and platelet counts \< 10\^5 /µL or ANC \< 10\^3 /µL Participants who never achieved CR or CRi or had no IWG disease assessment were considered to be non-responders in the calculation of CR + CRi rate.

    Time frame: Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.

  3. CR Plus CRi Rate by Initiation of Cycle 2

    The percentage of participants who achieved a CR or CRi by initiation of Cycle 2 of study treatment per the modified IWG criteria for AML and investigator assessment. CR: ANC ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRi: Lack of morphologic evidence of leukemia (blasts \< 5%), and platelet counts \< 10\^5 /µL or ANC \< 10\^3 /µL. Participants who never achieved CR or CRi or had no IWG disease assessment by initiation of Cycle 2 were considered to be non-responders in the calculation of CR + CRi rate by initiation of Cycle 2.

    Time frame: Cycle 2, Day 1

  4. Time to First Response of CR + CRi

    The time to the first response of CR + CRi is defined as the time from the first date of study drug to the first response of CR or CRi per the IWG AML response criteria assessed by the investigator. CR: absolute neutrophil count (ANC) ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRi: lack of morphologic evidence of leukemia (blasts \< 5%), and platelet counts \< 10\^5 /µL or ANC \< 10\^3 /µL.

    Time frame: Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.

  5. Time to Best Response of CR + CRi

    The time to the best response of CR + CRi is defined as the time from the first date of study drug to the best response of CR or CRi per the IWG AML response criteria assessed by the investigator. CR: absolute neutrophil count (ANC) ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRi: lack of morphologic evidence of leukemia (blasts \< 5%), and platelet counts \< 10\^5 /µL or ANC \< 10\^3 /µL.

    Time frame: Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.

  6. Complete Remission With Partial Hematologic Recovery (CRh) Rate

    Complete remission with partial hematologic recovery is a derived response based on bone marrow blast and hematology laboratory values. CRh rate is defined as the percentage of participants who achieved CRh as the best response at any time point during the study. A participant achieved a CRh when meeting the following criteria: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10\^3 /µL and * Peripheral blood platelet count of \> 0.5 × 10\^5 /µL and * A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection. Participants who never achieved CRh or did not have disease assessment or hematology data were considered to be non-responders in the calculation of CRh rate.

    Time frame: Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.

  7. CR Plus CRh Rate

    CR + CRh rate is defined as the percentage of participants who achieved CR or CRh at any time point during the study. CR: ANC ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRh is a derived response based on bone marrow blast and hematology lab values. A participant achieved a CRh when meeting the following criteria: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10\^3 /µL and * Peripheral blood platelet count of \> 0.5 × 10\^5 /µL and * A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection. Participants who never achieved CR/CRh or did not have disease assessment or hematology data were considered to be non-responders in the calculation of CR + CRh rate.

    Time frame: Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.

  8. CR Plus CRh Rate by Initiation of Cycle 2

    CR + CRh rate by initiation of Cycle 2 is defined as the percentage of participants who achieved CR or CRh by initiation of Cycle 2 of study treatment. CR: ANC ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRh is a derived response based on bone marrow blast and hematology lab values. A participant achieved a CRh when meeting the following criteria: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10\^3 /µL and * Peripheral blood platelet count of \> 0.5 × 10\^5 /µL and * A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection. Participants who never achieved CR/CRh or did not have disease assessment by initiation of Cycle 2 were considered to be non-responders in the calculation of CR + CRh rate by initiation of Cycle 2.

    Time frame: Cycle 2, Day 1

  9. Time to First Response of CR Plus CRh

    The time to the first response of CR + CRh is defined as the time from the first date of study drug to the first response of CR or CRh. CR: ANC ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRh is a derived response based on bone marrow blast and hematology lab values. A participant achieved a CRh when meeting the following criteria: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10\^3 /µL and * Peripheral blood platelet count of \> 0.5 × 10\^5 /µL and * A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection.

    Time frame: Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.

  10. Time to Best Response of CR Plus CRh

    The time to the best response of CR + CRh is defined as the time from the first date of study drug to the best response of CR or CRh. CR: ANC ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRh is a derived response based on bone marrow blast and hematology lab values. A participant achieved a CRh when meeting the following criteria: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10\^3 /µL and * Peripheral blood platelet count of \> 0.5 × 10\^5 /µL and * A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection.

    Time frame: Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.

  11. Best Response Based on IWG Criteria

    Best response determined using the IWG-AML response criteria during the course of treatment. * CR: ANC ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence, and bone marrow with \< 5% blasts; * CRi: lack of morphologic evidence of leukemia (blasts \< 5%), and platelet counts \< 10\^5 /µL or ANC \< 10\^3 /µL; * PR: all of the hematologic values for a CR but with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate; * MLFS: \< 5% blasts in an aspirate and/or bone marrow core sample; * RD: failure to achieve CR, CRi, PR; only including subjects surviving at least 7 days following completion of initial treatment cycle with evidence of persistent leukemia by blood and/or bone marrow examination; * PD: one or more of the following: ≥ 50% decrement from maximum response levels in neutrophils or platelets; a reduction in hemoglobin by at least 2 g/dL; or transfusion dependence not due to other toxicities and bone marrow blast ≥ 5%.

    Time frame: Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.

  12. Duration of Complete Response

    Duration of CR is defined as the time from date that a participant achieved CR to the first date of relapse, clinical disease progression or death due to disease progression, whichever occurred earliest. Duration of CR was estimated using Kaplan-Meier methodology. If a participant was still responding at the data cutoff date, then the participant's data were censored at their last disease assessment date. Disease assessment data after the onset of any post-treatment therapy were not included in the duration of CR analysis.

    Time frame: Median duration of follow-up was 44.5 months (range: 0.3 to 63.7)

  13. Duration of CR Plus CRi

    Duration of CR + CRi is defined as the time from the date that a participant achieved CR or CRi to the first date of relapse, clinical disease progression or death due to disease progression, whichever occurred earliest. Duration of CR + CRi was estimated using Kaplan-Meier methodology. If a participant was still responding at the data cutoff date, then the participant's data were censored at their last disease assessment date. Disease assessment data after the onset of any post-treatment therapy were not included in the analysis.

    Time frame: Median duration of follow-up was 44.5 months (range: 0.3 to 63.7)

  14. Duration of CRi

    Duration of CRi is defined as the time from date that a participant achieved CRi to the first date of relapse, clinical disease progression or death due to disease progression, whichever occurred earliest. Duration of CRi was estimated using Kaplan-Meier methodology. If a participant was still responding at the data cutoff date, then the participant's data were censored at their last disease assessment date. Disease assessment data after the onset of any post-treatment therapy were not included in the analysis.

    Time frame: Median duration of follow-up was 44.5 months (range: 0.3 to 63.7)

  15. Duration of CR Plus CRh

    Duration of CR + CRh is defined as the time from date that a participant achieved CR or CRh to the first date of relapse, clinical disease progression or death due to disease progression, whichever occurred earliest. Duration of CR + CRh was estimated using Kaplan-Meier methodology. If a participant was still responding at the data cutoff date, then the participant's data were censored at their last disease assessment date. Disease assessment data after the onset of any post-treatment therapy were not included in the analysis.

    Time frame: Median duration of follow-up was 44.5 months (range: 0.3 to 63.7)

  16. Overall Survival (OS)

    Overall survival is defined as the time from the date of first dose to the date of death. All events of death were included, regardless of whether the event occurred while the participant was still taking study drug, or after the participant discontinued study drug. OS was estimated using Kaplan-Meier methodology. Participants who were still alive were censored at the analysis date.

    Time frame: Median duration of follow-up was 44.5 months (range: 0.3 to 63.7)

  17. Post Baseline Transfusion Independence Rate

    Post baseline transfusion independence rate was estimated as the percentage of participants who achieved transfusion independence during the evaluation period. Post-baseline transfusion independence is defined as a period of at least 56 days (≥ 56 days) with no RBC or platelet transfusion during the evaluation period. The evaluation period is from the first dose of study drug to the last dose of study drug until the 30 day follow-up visit, disease progression (including clinical progression), or death, whichever was earlier. Results are reported for participants who achieved both RBC and platelet transfusion independence and for participants who received RBC transfusion independence and platelet transfusion independence.

    Time frame: From the first dose of study drug to the last dose of study drug plus 30 days, disease progression (including clinical progression), or death, whichever was earlier; median duration of treatment was 4.2 months.

  18. Post Baseline Transfusion Independence Rate Among Participants Transfusion-dependent at Baseline

    Post baseline transfusion independence rate was estimated as the percentage of participants who achieved transfusion independence during the evaluation period. Post-baseline transfusion independence is defined as a period of at least 56 days (≥ 56 days) with no RBC or platelet transfusion during the evaluation period. The evaluation period is from the first dose of study drug to the last dose of study drug until the 30 day follow-up visit, disease progression (including clinical progression), or death, whichever was earlier. Results are reported for participants who achieved both RBC and platelet transfusion independence and for participants who received RBC transfusion independence and platelet transfusion independence.

    Time frame: From the first dose of study drug to the last dose of study drug plus 30 days, disease progression (including clinical progression), or death, whichever was earlier; median duration of treatment was 4.2 months.

  19. Duration of Post Baseline Transfusion Independence

    The duration of transfusion independence is defined as the first time period that a participant received no RBC/platelet transfusions for at least 56 days during the evaluation period. Post-baseline transfusion independence is defined as a period of at least 56 days with no RBC or platelet transfusion during the evaluation period. The evaluation period is from the first dose of study drug to the last dose of study drug until the 30 day follow-up visit, disease progression (including clinical progression), or death, whichever was earlier.

    Time frame: From the first dose of study drug to the last dose of study drug plus 30 days, disease progression (including clinical progression), or death, whichever was earlier; median duration of treatment was 4.2 months.

07

Results

Posted Aug 29, 2022

Participant flow

Previously untreated adults with acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy were enrolled at nine study sites in the United States, Australia, Germany, and Italy between December 2014 and May 2017. The study consisted of a dose escalation phase (Phase 1) to determine the recommended Phase 2 dose (RPTD), and a dose expansion phase (Phase 2).

Participant flow — Overall Study
MilestonePhase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDACPhase 2: 600 mg Venetoclax + LDAC
Started81076
Treated81074
Completed000
Not completed81076
Withdrew: Adverse event not related to progression1210
Withdrew: Adverse event related to progression028
Withdrew: Physician decision124
Withdrew: Progressive disease with death0010
Withdrew: Progressive disease without death2320
Withdrew: Withdrawal by subject117
Withdrew: Other3015
Withdrew: Did not receive treatment002

Outcome measures

PrimaryPhase 1: Number of Participants With Dose-limiting Toxicities

Dose-limiting toxicities (DLTs) were determined during cycle 1 of the dose-escalation phase and defined as Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 grade 4 (life threatening requiring urgent intervention) or 5 (resulted in death) toxicity, excluding adverse events commonly caused by AML (eg, neutropenia, fever). Hematologic DLT was defined as failure of platelet recovery to 25 × 10\^9/L or greater and absolute neutrophil count (ANC) to 0.5 × 10\^9/L or greater within 14 days of the last dose of venetoclax in the absence of residual AML.

Time frame:
Up to 28 days (Cycle 1)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Dose-limiting Toxicities
ParticipantsPhase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDAC
Phase 1: Number of Participants With Dose-limiting Toxicities01
PrimaryPhase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax

The highest concentration that a drug achieves in the blood after administration in a dosing interval.

Time frame:
Cycle 1, Day 10 at predose and 2, 4, 6, 8, and 24 hours postdose (venetoclax with LDAC); Cycle 1, Day 18 at predose, 2, 4, 6, 8, and 24 hours postdose (venetoclax alone)
Reported as:
Mean · µg/mL
Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax
µg/mLPhase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDAC
Cycle 1, Day 10 (Venetoclax with LDAC)2.04 ± 1.452.26 ± 0.930
Cycle 1, Day 18 (Venetoclax alone)2.92 ± 2.152.36 ± 1.22
PrimaryPhase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax

The time at which the maximum plasma concentration (Cmax) is observed.

Time frame:
Cycle 1, Day 10 at predose and 2, 4, 6, 8, and 24 hours postdose (venetoclax with LDAC); Cycle 1, Day 18 at predose, 2, 4, 6, 8, and 24 hours postdose (venetoclax alone)
Reported as:
Median · hours
Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax
hoursPhase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDAC
Cycle 1, Day 10 (Venetoclax with LDAC)4.0 (4.0 to 6.0)8.0 (4.0 to 8.0)
Cycle 1, Day 18 (Venetoclax Alone)7.0 (3.5 to 8.0)6.6 (4.0 to 8.0)
PrimaryPhase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax
Time frame:
Cycle 1, Day 10 at predose and 2, 4, 6, 8, and 24 hours postdose (venetoclax with LDAC); Cycle 1, Day 18 at predose, 2, 4, 6, 8, and 24 hours postdose (venetoclax alone)
Reported as:
Mean · µg*h/mL
Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax
µg*h/mLPhase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDAC
Cycle 1, Day 10 (Venetoclax with LDAC)33.3 ± 27.533.4 ± 14.1
Cycle 1, Day 18 (Venetoclax Alone)51.8 ± 36.935.4 ± 19.8
PrimaryPhase 1: Maximum Observed Plasma Concentration (Cmax) of Cytarabine

The highest concentration that a drug achieves in the blood after administration in a dosing interval.

Time frame:
Cycle 1, Day 1 and Day 10 at pre-dose and at 15 and 30 minutes and 1, 3, 6 hours post-dose.
Reported as:
Mean · ng/mL
Phase 1: Maximum Observed Plasma Concentration (Cmax) of Cytarabine
ng/mLPhase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDAC
Cycle 1, Day 1 (LDAC Alone)175 ± 47.0174 ± 55.4
Cycle 1, Day 10 (LDAC with Venetoclax)166 ± 32.1175 ± 62.3
PrimaryPhase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Cytarabine

The time at which the maximum plasma concentration (Cmax) is observed.

Time frame:
Cycle 1, Day 1 and Day 10 at pre-dose and at 15 and 30 minutes and 1, 3, 6 hours post-dose.
Reported as:
Median · hours
Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Cytarabine
hoursPhase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDAC
Cycle 1, Day 1 (LDAC Alone)0.3 (0.3 to 0.4)0.3 (0.2 to 0.5)
Cycle 1, Day 10 (LDAC with Venetoclax)0.3 (0.3 to 0.5)0.3 (0.2 to 0.5)
PrimaryPhase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to Last Measurable Concentration (AUCt) of Cytarabine
Time frame:
Cycle 1, Day 1 and Day 10 at pre-dose and at 15 and 30 minutes and 1, 3, 6 hours post-dose.
Reported as:
Mean · ng*h/mL
Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to Last Measurable Concentration (AUCt) of Cytarabine
ng*h/mLPhase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDAC
Cycle 1, Day 1 (LDAC Alone)194 ± 66.3204 ± 62.9
Cycle 1, Day 10 (LDAC with Venetoclax)231 ± 89.0202 ± 54.9
PrimaryOverall Response Rate

Overall response rate (ORR) is defined as the percentage of participants who achieved a complete remission (CR), complete remission with incomplete marrow recovery (CRi), or partial remission (PR) per the International Working Group (IWG) for AML response criteria, per investigator assessment. CR: absolute neutrophil count (ANC) ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, red blood cell (RBC) transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRi: lack of morphologic evidence of leukemia (blasts \< 5%), and platelet counts \< 10\^5 /µL or ANC \< 10\^3 /µL. PR: all of the hematologic values for a CR but with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate.

Time frame:
Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsPhase 1+2: 600 mg Venetoclax + LDAC
Overall Response Rate54.9 (43.5 to 65.9)
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator rated the severity of each AE according to the CTCAE Version 4.0 and the following: Grade 1: The AE is transient and easily tolerated (mild). Grade 2: The AE causes discomfort and interrupts usual activities (moderate). Grade 3: The AE causes considerable interference with usual activities and may be incapacitating (moderate to severe). Grade 4: The AE is life threatening requiring urgent intervention. Grade 5: The AE resulted in death. The investigator assessed each event as either having a reasonable possibility or no reasonable possibility of being related to the use of study drug. Treatment-emergent events are defined as events that began or worsened in severity after the first dose of study drug.

Time frame:
From first dose of study drug until 30 days after last dose of study drug; median (minimum, maximum) duration of treatment was 4.1 (0.2, 62.8) months overall.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPhase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDACPhase 2: 600 mg Venetoclax + LDAC
Any treatment-emergent adverse event (TEAE)81074
TEAE with CTCAE Grade 3 or 481072
TEAE with CTCAE Grade 3 or above81072
Venetoclax-related TEAE8966
LDAC-related TEAE8971
TEAE leading to hospitalization7864
TEAE leading to venetoclax discontinuation3524
TEAE leading to LDAC discontinuation3526
TEAE leading to venetoclax interruption3445
TEAE leading to LDAC interruption3338
TEAE leading to venetoclax reduction016
TEAE leading to LDAC reduction001
TEAE leading to death1415
SecondaryComplete Remission Rate

Complete remission (CR) rate is defined as the percentage of participants who achieved a complete remission at any time point during the study per the modified IWG criteria for AML and investigator assessment. CR: absolute neutrophil count (ANC) ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, red blood cell (RBC) transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. Participants who never achieved CR or had no IWG disease assessment were considered to be non-responders in the calculation of CR rate.

Time frame:
Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.
Reported as:
Number · percentage of participants
Complete Remission Rate
percentage of participantsPhase 1+2: 600 mg Venetoclax + LDAC
Complete Remission Rate25.6 (16.6 to 36.4)
SecondaryComplete Remission Plus CR With Incomplete Blood Count Recovery (CRi) Rate

The percentage of participants who achieved a CR or CRi at any time point during the study per the modified IWG criteria for AML and investigator assessment. CR: absolute neutrophil count (ANC) ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, red blood cell (RBC) transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRi: lack of morphologic evidence of leukemia (blasts \< 5%), and platelet counts \< 10\^5 /µL or ANC \< 10\^3 /µL Participants who never achieved CR or CRi or had no IWG disease assessment were considered to be non-responders in the calculation of CR + CRi rate.

Time frame:
Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.
Reported as:
Number · percentage of participants
Complete Remission Plus CR With Incomplete Blood Count Recovery (CRi) Rate
percentage of participantsPhase 1+2: 600 mg Venetoclax + LDAC
Complete Remission Plus CR With Incomplete Blood Count Recovery (CRi) Rate53.7 (42.3 to 64.7)
SecondaryCR Plus CRi Rate by Initiation of Cycle 2

The percentage of participants who achieved a CR or CRi by initiation of Cycle 2 of study treatment per the modified IWG criteria for AML and investigator assessment. CR: ANC ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRi: Lack of morphologic evidence of leukemia (blasts \< 5%), and platelet counts \< 10\^5 /µL or ANC \< 10\^3 /µL. Participants who never achieved CR or CRi or had no IWG disease assessment by initiation of Cycle 2 were considered to be non-responders in the calculation of CR + CRi rate by initiation of Cycle 2.

Time frame:
Cycle 2, Day 1
Reported as:
Number · percentage of participants
CR Plus CRi Rate by Initiation of Cycle 2
percentage of participantsPhase 1+2: 600 mg Venetoclax + LDAC
CR Plus CRi Rate by Initiation of Cycle 228.0 (18.7 to 39.1)
SecondaryTime to First Response of CR + CRi

The time to the first response of CR + CRi is defined as the time from the first date of study drug to the first response of CR or CRi per the IWG AML response criteria assessed by the investigator. CR: absolute neutrophil count (ANC) ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRi: lack of morphologic evidence of leukemia (blasts \< 5%), and platelet counts \< 10\^5 /µL or ANC \< 10\^3 /µL.

Time frame:
Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.
Reported as:
Median · months
Time to First Response of CR + CRi
monthsPhase 1+2: 600 mg Venetoclax + LDAC
Time to First Response of CR + CRi1.4 (0.8 to 14.9)
SecondaryTime to Best Response of CR + CRi

The time to the best response of CR + CRi is defined as the time from the first date of study drug to the best response of CR or CRi per the IWG AML response criteria assessed by the investigator. CR: absolute neutrophil count (ANC) ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRi: lack of morphologic evidence of leukemia (blasts \< 5%), and platelet counts \< 10\^5 /µL or ANC \< 10\^3 /µL.

Time frame:
Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.
Reported as:
Median · months
Time to Best Response of CR + CRi
monthsPhase 1+2: 600 mg Venetoclax + LDAC
Time to Best Response of CR + CRi2.8 (0.8 to 22.4)
SecondaryComplete Remission With Partial Hematologic Recovery (CRh) Rate

Complete remission with partial hematologic recovery is a derived response based on bone marrow blast and hematology laboratory values. CRh rate is defined as the percentage of participants who achieved CRh as the best response at any time point during the study. A participant achieved a CRh when meeting the following criteria: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10\^3 /µL and * Peripheral blood platelet count of \> 0.5 × 10\^5 /µL and * A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection. Participants who never achieved CRh or did not have disease assessment or hematology data were considered to be non-responders in the calculation of CRh rate.

Time frame:
Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.
Reported as:
Number · percentage of participants
Complete Remission With Partial Hematologic Recovery (CRh) Rate
percentage of participantsPhase 1+2: 600 mg Venetoclax + LDAC
Complete Remission With Partial Hematologic Recovery (CRh) Rate20.7 (12.6 to 31.1)
SecondaryCR Plus CRh Rate

CR + CRh rate is defined as the percentage of participants who achieved CR or CRh at any time point during the study. CR: ANC ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRh is a derived response based on bone marrow blast and hematology lab values. A participant achieved a CRh when meeting the following criteria: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10\^3 /µL and * Peripheral blood platelet count of \> 0.5 × 10\^5 /µL and * A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection. Participants who never achieved CR/CRh or did not have disease assessment or hematology data were considered to be non-responders in the calculation of CR + CRh rate.

Time frame:
Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.
Reported as:
Number · percentage of participants
CR Plus CRh Rate
percentage of participantsPhase 1+2: 600 mg Venetoclax + LDAC
CR Plus CRh Rate46.3 (35.3 to 57.7)
SecondaryCR Plus CRh Rate by Initiation of Cycle 2

CR + CRh rate by initiation of Cycle 2 is defined as the percentage of participants who achieved CR or CRh by initiation of Cycle 2 of study treatment. CR: ANC ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRh is a derived response based on bone marrow blast and hematology lab values. A participant achieved a CRh when meeting the following criteria: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10\^3 /µL and * Peripheral blood platelet count of \> 0.5 × 10\^5 /µL and * A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection. Participants who never achieved CR/CRh or did not have disease assessment by initiation of Cycle 2 were considered to be non-responders in the calculation of CR + CRh rate by initiation of Cycle 2.

Time frame:
Cycle 2, Day 1
Reported as:
Number · percentage of participants
CR Plus CRh Rate by Initiation of Cycle 2
percentage of participantsPhase 1+2: 600 mg Venetoclax + LDAC
CR Plus CRh Rate by Initiation of Cycle 230.5 (20.8 to 41.6)
SecondaryTime to First Response of CR Plus CRh

The time to the first response of CR + CRh is defined as the time from the first date of study drug to the first response of CR or CRh. CR: ANC ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRh is a derived response based on bone marrow blast and hematology lab values. A participant achieved a CRh when meeting the following criteria: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10\^3 /µL and * Peripheral blood platelet count of \> 0.5 × 10\^5 /µL and * A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection.

Time frame:
Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.
Reported as:
Median · months
Time to First Response of CR Plus CRh
monthsPhase 1+2: 600 mg Venetoclax + LDAC
Time to First Response of CR Plus CRh1.0 (0.8 to 9.4)
SecondaryTime to Best Response of CR Plus CRh

The time to the best response of CR + CRh is defined as the time from the first date of study drug to the best response of CR or CRh. CR: ANC ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \< 5% blasts. CRh is a derived response based on bone marrow blast and hematology lab values. A participant achieved a CRh when meeting the following criteria: * Bone marrow with \< 5% blasts and * Peripheral blood neutrophil count of \> 0.5 × 10\^3 /µL and * Peripheral blood platelet count of \> 0.5 × 10\^5 /µL and * A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection.

Time frame:
Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.
Reported as:
Median · months
Time to Best Response of CR Plus CRh
monthsPhase 1+2: 600 mg Venetoclax + LDAC
Time to Best Response of CR Plus CRh2.6 (0.8 to 22.4)
SecondaryBest Response Based on IWG Criteria

Best response determined using the IWG-AML response criteria during the course of treatment. * CR: ANC ≥ 10\^3 /µL, platelet counts ≥ 10\^5 /µL, RBC transfusion independence, and bone marrow with \< 5% blasts; * CRi: lack of morphologic evidence of leukemia (blasts \< 5%), and platelet counts \< 10\^5 /µL or ANC \< 10\^3 /µL; * PR: all of the hematologic values for a CR but with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate; * MLFS: \< 5% blasts in an aspirate and/or bone marrow core sample; * RD: failure to achieve CR, CRi, PR; only including subjects surviving at least 7 days following completion of initial treatment cycle with evidence of persistent leukemia by blood and/or bone marrow examination; * PD: one or more of the following: ≥ 50% decrement from maximum response levels in neutrophils or platelets; a reduction in hemoglobin by at least 2 g/dL; or transfusion dependence not due to other toxicities and bone marrow blast ≥ 5%.

Time frame:
Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.
Reported as:
Count of participants · Participants
Best Response Based on IWG Criteria
ParticipantsPhase 1+2: 600 mg Venetoclax + LDAC
Complete Remission (CR)21
Complete Remission with Incomplete Marrow Recovery (CRi)23
Partial Remission (PR)1
Morphologically Leukemia Free State (MLFS)6
Resistant Disease (RD)19
Disease Progression (PD)4
Discontinued With No Response Data (DS)8
SecondaryDuration of Complete Response

Duration of CR is defined as the time from date that a participant achieved CR to the first date of relapse, clinical disease progression or death due to disease progression, whichever occurred earliest. Duration of CR was estimated using Kaplan-Meier methodology. If a participant was still responding at the data cutoff date, then the participant's data were censored at their last disease assessment date. Disease assessment data after the onset of any post-treatment therapy were not included in the duration of CR analysis.

Time frame:
Median duration of follow-up was 44.5 months (range: 0.3 to 63.7)
Reported as:
Median · months
Duration of Complete Response
monthsPhase 1+2: 600 mg Venetoclax + LDAC
Duration of Complete Response14.8 (7.2 to NA)
SecondaryDuration of CR Plus CRi

Duration of CR + CRi is defined as the time from the date that a participant achieved CR or CRi to the first date of relapse, clinical disease progression or death due to disease progression, whichever occurred earliest. Duration of CR + CRi was estimated using Kaplan-Meier methodology. If a participant was still responding at the data cutoff date, then the participant's data were censored at their last disease assessment date. Disease assessment data after the onset of any post-treatment therapy were not included in the analysis.

Time frame:
Median duration of follow-up was 44.5 months (range: 0.3 to 63.7)
Reported as:
Median · months
Duration of CR Plus CRi
monthsPhase 1+2: 600 mg Venetoclax + LDAC
Duration of CR Plus CRi9.8 (5.3 to 14.9)
SecondaryDuration of CRi

Duration of CRi is defined as the time from date that a participant achieved CRi to the first date of relapse, clinical disease progression or death due to disease progression, whichever occurred earliest. Duration of CRi was estimated using Kaplan-Meier methodology. If a participant was still responding at the data cutoff date, then the participant's data were censored at their last disease assessment date. Disease assessment data after the onset of any post-treatment therapy were not included in the analysis.

Time frame:
Median duration of follow-up was 44.5 months (range: 0.3 to 63.7)
Reported as:
Median · months
Duration of CRi
monthsPhase 1+2: 600 mg Venetoclax + LDAC
Duration of CRi4.7 (2.6 to 5.6)
SecondaryDuration of CR Plus CRh

Duration of CR + CRh is defined as the time from date that a participant achieved CR or CRh to the first date of relapse, clinical disease progression or death due to disease progression, whichever occurred earliest. Duration of CR + CRh was estimated using Kaplan-Meier methodology. If a participant was still responding at the data cutoff date, then the participant's data were censored at their last disease assessment date. Disease assessment data after the onset of any post-treatment therapy were not included in the analysis.

Time frame:
Median duration of follow-up was 44.5 months (range: 0.3 to 63.7)
Reported as:
Median · months
Duration of CR Plus CRh
monthsPhase 1+2: 600 mg Venetoclax + LDAC
Duration of CR Plus CRh11.0 (6.1 to 28.2)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from the date of first dose to the date of death. All events of death were included, regardless of whether the event occurred while the participant was still taking study drug, or after the participant discontinued study drug. OS was estimated using Kaplan-Meier methodology. Participants who were still alive were censored at the analysis date.

Time frame:
Median duration of follow-up was 44.5 months (range: 0.3 to 63.7)
Reported as:
Median · months
Overall Survival (OS)
monthsPhase 1+2: 600 mg Venetoclax + LDAC
Overall Survival (OS)9.7 (5.7 to 14.0)
SecondaryPost Baseline Transfusion Independence Rate

Post baseline transfusion independence rate was estimated as the percentage of participants who achieved transfusion independence during the evaluation period. Post-baseline transfusion independence is defined as a period of at least 56 days (≥ 56 days) with no RBC or platelet transfusion during the evaluation period. The evaluation period is from the first dose of study drug to the last dose of study drug until the 30 day follow-up visit, disease progression (including clinical progression), or death, whichever was earlier. Results are reported for participants who achieved both RBC and platelet transfusion independence and for participants who received RBC transfusion independence and platelet transfusion independence.

Time frame:
From the first dose of study drug to the last dose of study drug plus 30 days, disease progression (including clinical progression), or death, whichever was earlier; median duration of treatment was 4.2 months.
Reported as:
Number · percentage of participants
Post Baseline Transfusion Independence Rate
percentage of participantsPhase 1+2: 600 mg Venetoclax + LDAC
RBC and platelet transfusion independence45.1 (34.1 to 56.5)
RBC transfusion independence47.6 (36.4 to 58.9)
Platelet transfusion independence58.5 (47.1 to 69.3)
SecondaryPost Baseline Transfusion Independence Rate Among Participants Transfusion-dependent at Baseline

Post baseline transfusion independence rate was estimated as the percentage of participants who achieved transfusion independence during the evaluation period. Post-baseline transfusion independence is defined as a period of at least 56 days (≥ 56 days) with no RBC or platelet transfusion during the evaluation period. The evaluation period is from the first dose of study drug to the last dose of study drug until the 30 day follow-up visit, disease progression (including clinical progression), or death, whichever was earlier. Results are reported for participants who achieved both RBC and platelet transfusion independence and for participants who received RBC transfusion independence and platelet transfusion independence.

Time frame:
From the first dose of study drug to the last dose of study drug plus 30 days, disease progression (including clinical progression), or death, whichever was earlier; median duration of treatment was 4.2 months.
Reported as:
Number · percentage of participants
Post Baseline Transfusion Independence Rate Among Participants Transfusion-dependent at Baseline
percentage of participantsPhase 1+2: 600 mg Venetoclax + LDAC
RBC and platelet transfusion independence45.0 (32.1 to 58.4)
RBC transfusion independence45.3 (31.6 to 59.6)
Platelet transfusion independence60.9 (38.5 to 80.3)
SecondaryDuration of Post Baseline Transfusion Independence

The duration of transfusion independence is defined as the first time period that a participant received no RBC/platelet transfusions for at least 56 days during the evaluation period. Post-baseline transfusion independence is defined as a period of at least 56 days with no RBC or platelet transfusion during the evaluation period. The evaluation period is from the first dose of study drug to the last dose of study drug until the 30 day follow-up visit, disease progression (including clinical progression), or death, whichever was earlier.

Time frame:
From the first dose of study drug to the last dose of study drug plus 30 days, disease progression (including clinical progression), or death, whichever was earlier; median duration of treatment was 4.2 months.
Reported as:
Median · days
Duration of Post Baseline Transfusion Independence
daysPhase 1+2: 600 mg Venetoclax + LDAC
Duration of RBC and platelet transfusion independence150 (56 to 1855)
Duration of RBC transfusion independence123 (56 to 1881)
Duration of platelet transfusion independence155.5 (56 to 1855)

Adverse events

Collected over All-cause mortality is reported from enrollment through the end of study; maximum time on study was 63.7 months. Adverse events are reported from first dose of study drug until 30 days after last dose of study drug; median (minimum, maximum) duration of treatment was 4.1 (0.2, 62.8) months overall.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: 600 mg Venetoclax + LDAC6/8 (75%)7/8 (87.5%)8/8 (100%)
Phase 1: 800 mg Venetoclax + LDAC10/10 (100%)9/10 (90%)10/10 (100%)
Phase 2: 600 mg Venetoclax + LDAC63/76 (82.9%)68/74 (91.9%)74/74 (100%)
Most frequent serious events
Showing 10 of 135
Most frequent serious events
EventPhase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDACPhase 2: 600 mg Venetoclax + LDAC
PYREXIAGeneral disorders1/84/102/74
FEBRILE NEUTROPENIABlood and lymphatic system disorders1/83/1022/74
PNEUMONIAInfections and infestations2/81/1011/74
HYPONATRAEMIAMetabolism and nutrition disorders2/80/100/74
MALIGNANT NEOPLASM PROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/82/105/74
ACUTE CORONARY SYNDROMECardiac disorders1/80/100/74
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/80/101/74
ASTHENIAGeneral disorders1/80/102/74
NON-CARDIAC CHEST PAINGeneral disorders1/80/100/74
ESCHERICHIA URINARY TRACT INFECTIONInfections and infestations1/80/100/74
Most frequent other events
Showing 10 of 186
Most frequent other events
EventPhase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDACPhase 2: 600 mg Venetoclax + LDAC
NAUSEAGastrointestinal disorders8/86/1048/74
FATIGUEGeneral disorders7/83/1028/74
DIARRHOEAGastrointestinal disorders6/82/1034/74
ANAEMIABlood and lymphatic system disorders5/82/1019/74
DECREASED APPETITEMetabolism and nutrition disorders5/82/1025/74
NEUTROPENIABlood and lymphatic system disorders4/84/1019/74
THROMBOCYTOPENIABlood and lymphatic system disorders4/84/1026/74
HYPOKALAEMIAMetabolism and nutrition disorders4/83/1036/74
WHITE BLOOD CELL COUNT DECREASEDInvestigations0/82/1028/74
VOMITINGGastrointestinal disorders3/83/1021/74

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)Phase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDACPhase 2: 600 mg Venetoclax + LDACTotal
Mean75.3 ± 6.4574.4 ± 3.7275.0 ± 5.5674.9 ± 5.43
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDACPhase 2: 600 mg Venetoclax + LDACTotal
Female332733
Male574961
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1: 600 mg Venetoclax + LDACPhase 1: 800 mg Venetoclax + LDACPhase 2: 600 mg Venetoclax + LDACTotal
White8106987
Black or African American0022
Asian0022
Missing0033
08

Study locations

9 sites
  • Univ Kansas Med Ctr /ID# 131175
    Kansas City, Kansas 66160, United States
  • Weill Cornell Medical College /ID# 131170
    New York, New York 10065, United States
  • University of Pittsburgh MC /ID# 131168
    Pittsburgh, Pennsylvania 15260, United States
  • Vanderbilt University Medical Center /ID# 131177
    Nashville, Tennessee 37232-0011, United States
  • Fred Hutchinson Cancer Research Center /ID# 131178
    Seattle, Washington 98109-1024, United States
  • Calvary Mater Newcastle /ID# 136076
    Waratah, New South Wales 2298, Australia
  • Alfred Health /ID# 131180
    Melbourne, Victoria 3004, Australia
  • Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 133979
    Hamburg, 20246, Germany
  • Duplicate_A.O.U. Policlinico S.Orsola-Malpighi /ID# 131183
    Bologna, Emilia-Romagna 40138, Italy
09

References and documents

Publications

  • Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20. PubMed 30892988 ↗
  • Badawi M, Chen X, Marroum P, Suleiman AA, Mensing S, Koenigsdorfer A, Schiele JT, Palenski T, Samineni D, Hoffman D, Menon R, Salem AH. Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet. Clin Drug Investig. 2022 Aug;42(8):657-668. doi: 10.1007/s40261-022-01172-4. Epub 2022 Jul 13. PubMed 35829925 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Aug 2021, 79 months.

Results were first posted in Aug 2022, 1 year after primary completion.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 79 months is close to that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2014
First posted
Nov 10, 2014
StartActual
Dec 31, 2014
Primary completionActual
Aug 10, 2021
CompletionActual
Aug 10, 2021
Results first posted
Aug 29, 2022
Last update
Aug 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02287233
Lead sponsor
AbbVie
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 10, 2014
Start date
Dec 31, 2014
Primary completion
Aug 10, 2021
Completion
Aug 10, 2021
Results posted
Aug 29, 2022
Last update
Aug 29, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion